---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-096599"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-04-10T23:59:59+00:00"
generated_at: "2026-06-17T04:21:19.682765+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Zymeworks appoints Derek Miller to board of directors

## Summary
- Appointed as Class II director, term expiring at 2023 annual meeting.
- Received initial stock option grant for 50,000 shares of common stock.
- Over 25 years biotech experience, former CBO of Celator and Aro Biotherapeutics.

## SEC filing metadata
- accession: 0001193125-23-096599
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523096599/0001193125-23-096599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523096599/d495408d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-096599
- JSON: https://secwatch.observer/filing/0001193125-23-096599.json
- Plain text: https://secwatch.observer/filing/0001193125-23-096599.txt

## Key facts
- Executive change
  Derek Miller was appointed as Director at Zymeworks Inc..
  - Action: appointed
  - Role: Director
  source text: voted to appoint Derek Miller as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523096599/0001193125-23-096599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.